A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)

Trial Profile

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary)
  • Indications Alcoholic hepatitis; Liver failure
  • Focus Registrational; Therapeutic Use
  • Sponsors Vital Therapies
  • Most Recent Events

    • 07 Mar 2017 According to a Vital Therapies media release, this study was presented at the Asian Pacific Association for the Study of the Liver (APASL) meeting.
    • 09 Jan 2017 Dr. Tarek Hassanein is a physician investigator of this trial, according to a Vital Therapies media release.
    • 08 Mar 2016 According to a Vital Therapies media release, metabolomics study of samples from 8 ELAD-treated and 8 control subjects from this study will be presented at a future medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top